Novartis AG (NVS) suffered its steepest single-day selloff in more than six years on Monday, with European-listed shares tumbling more than 9% as investors digested a rare cluster of clinical failures that has cast a shadow over the Swiss drugmaker’s growth strategy.
The rout was triggered by the latest blow: a Phase III trial of del-desiran, a muscle-wasting disease therapy acquired through the $12 billion takeover of Avidity Biosciences in 2025, failed to achieve its primary endpoint. That miss came just days after pelacarsen, a cardiovascular drug once seen as a potential blockbuster, disappointed in a pivotal outcomes study, and an experimental cell therapy called rap-cel was paused across eight trials following the deaths of three patients.
By the close of trading, the Zurich-listed stock had erased roughly CHF 4.9 billion in market value on the pelacarsen news alone, according to Reuters estimates. The additional del-desiran failure on Monday compounded the damage, pushing the decline to levels not seen since March 2020.
del-desiran Misses Primary Endpoint in HARBOR Study
The HARBOR study, which enrolled 150 patients with myotonic dystrophy type 1 (DM1), tested whether del-desiran — an antibody-oligonucleotide conjugate administered intravenously — could improve video hand opening time (vHOT) over a 54-week treatment period. The measure captures how long it takes a patient to relax hand muscles after a forceful squeeze, a core functional deficit in DM1.
Novartis said the drug did not demonstrate a statistically significant improvement versus placebo on that primary endpoint. The company noted that del-desiran showed “signs of clinical activity” in secondary endpoints and exploratory analyses, though detailed data have not yet been released. Secondary measures in the trial included hand grip strength, walking or running ability, overall muscle strength, and daily functioning.
Shreeram Aradhye, Novartis’s chief medical officer, said the company will “continue to explore the full HARBOR dataset” before deciding on next steps for the program. DM1, a progressive genetic disorder that causes skeletal muscle wasting, affects an estimated 9.27 per 100,000 people and is the most common form of muscular dystrophy in adults of European ancestry. No disease-modifying therapy is currently approved for the condition.
The failure has particular resonance because del-desiran was the centerpiece asset in Novartis’s acquisition of Avidity. The deal also brought two other candidates into the pipeline: del-zota for Duchenne muscular dystrophy and del-brax for facioscapulohumeral muscular dystrophy. In a July 2026 research note, Jefferies analysts wrote that the HARBOR trial “needed to deliver” to justify the acquisition price. The outcome now raises uncomfortable questions about whether that bet was sound.
Pelacarsen Fails to Cut Cardiovascular Events
The del-desiran setback followed Friday’s announcement that pelacarsen, designed to lower lipoprotein(a), did not significantly reduce the risk of heart attacks, strokes, cardiovascular deaths, or urgent coronary procedures compared with placebo in the Phase III Lp(a)HORIZON trial.
The study enrolled 8,323 patients with elevated Lp(a), a genetically determined blood fat linked to heart disease. While pelacarsen successfully lowered Lp(a) levels, that reduction did not translate into fewer clinical events — a result that raises fundamental questions about the therapeutic hypothesis underpinning an entire class of drugs in development.
“These are not the results we hoped for,” Aradhye said, adding that the data still “advances scientific understanding of the relationship between Lp(a) lowering and cardiovascular outcomes.” Full results will be presented at a future medical congress.
Analysts had modeled peak annual sales of $3 billion to $6 billion for pelacarsen if the outcomes trial had succeeded. The failure also introduces uncertainty for competing Lp(a)-lowering drugs in late-stage development at Amgen and Eli Lilly, whose olpasiran and lepodisiran programs are built on a similar mechanism. No Lp(a)-targeting therapy is currently approved, despite elevated levels affecting roughly one in five people worldwide.
Barclays analysts said a second Novartis Lp(a) candidate, DII235, now appears “unlikely to bring any significant benefit” given the broader setback.
rap-cel Pause Adds to Clinical Woes
Compounding the pressure, Novartis’s experimental cell therapy rap-cel was placed on hold across eight clinical trials after three patient deaths. The company has not disclosed full details of the safety signals, but the pause removes another program from the near-term pipeline narrative and adds a safety overhang to an already difficult week.
Growth Target Under Scrutiny
The string of failures has forced investors to reconsider whether Novartis can meet its stated goal of 5% to 6% average annual sales growth through 2030. Jefferies said that target “is likely to be seen as unachievable” unless the company pursues further acquisitions to fill the gap.
The stakes are heightened by looming patent expiries on two of Novartis’s biggest revenue generators: the heart failure drug Entresto and the autoimmune therapy Cosentyx. Both are expected to lose market exclusivity in the coming years, removing billions in annual sales that the pipeline was supposed to replace.
Barclays noted that del-desiran and pelacarsen had together represented roughly $5 billion in potential peak sales. With both programs now in question, the bank expects Novartis shares to underperform the sector and sees the company’s roughly 20% valuation premium over peers narrowing.
Remibrutinib Offers a Bright Spot
Not all news from the pipeline has been negative. Last week, Novartis reported that remibrutinib, a Bruton’s tyrosine kinase inhibitor, delivered positive Phase III results in relapsing multiple sclerosis, showing a clinically meaningful slowing of disability progression. Data from another remibrutinib study in hidradenitis suppurativa, a chronic skin condition, is expected later this year.
Jefferies said the multiple sclerosis success “should make the pelacarsen conclusion more palatable” for investors, but the market’s reaction suggests that one win is not enough to offset three simultaneous losses.
Attention now turns to del-brax, the third Avidity-derived asset, which is not expected to report Phase III data until 2028 at the earliest. That timeline leaves a multi-year window during which Novartis will need to rely on other pipeline assets and potential dealmaking to sustain growth.
The company reported second-quarter sales of $14.41 billion and free cash flow of $5.56 billion, underscoring that its current business remains robust. But the market is forward-looking, and the message from this week’s trading is unambiguous: investors are no longer willing to price in pipeline success that has yet to materialize.
Novartis shares had risen roughly 20% this year through Friday’s close, driven by optimism about its development portfolio. Much of that premium has now evaporated in a single session, leaving the next clinical readouts — particularly del-brax and the broader remibrutinib program — as critical inflection points for restoring confidence.